The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
Sasaki
Takaaki
T
Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, D820, 44 Binney Street, Boston, MA 02115, USA.
Okuda
Katsuhiro
K
Zheng
Wei
W
Butrynski
James
J
Capelletti
Marzia
M
Wang
Liping
L
Gray
Nathanael S
NS
Wilner
Keith
K
Christensen
James G
JG
Demetri
George
G
Shapiro
Geoffrey I
GI
Rodig
Scott J
SJ
Eck
Michael J
MJ
Jänne
Pasi A
PA
D000077548:Anaplastic Lymphoma Kinase; D002460:Cell Line; D000077547:Crizotinib; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D009154:Mutation; D009379:Neoplasms, Muscle Tissue / Q000188:drug therapy* / Q000201:enzymology* / Q000235:genetics; D009447:Neuroblastoma / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics*; D011720:Pyrazoles / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology*; D020794:Receptor Protein-Tyrosine Kinases; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014178:Translocation, Genetic
C522504:EML4-ALK fusion protein, human; D015514:Oncogene Proteins, Fusion; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D011505:Protein-Tyrosine Kinases; D020794:Receptor Protein-Tyrosine Kinases